Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

ContraFect Corporation (CFRX)

2.08   0.16 (8.33%) 03-24 15:59
Open: 1.92 Pre. Close: 1.92
High: 2.14 Low: 1.9
Volume: 121,507 Market Cap: 3(M)

Technical analysis

as of: 2023-03-24 4:24:48 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 5.79     One year: 8.11
Support: Support1: 1.75    Support2: 1.45
Resistance: Resistance1: 4.96    Resistance2: 6.94
Pivot: 2.19
Moving Average: MA(5): 1.95     MA(20): 2.52
MA(100): 7.45     MA(250): 88.2
MACD: MACD(12,26): -0.8     Signal(9): -0.9
Stochastic oscillator: %K(14,3): 15.8     %D(3): 13.2
RSI: RSI(14): 35
52-week: High: 363.2  Low: 1.75
Average Vol(K): 3-Month: 669 (K)  10-Days: 106 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CFRX ] has closed above bottom band by 40.6%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.14 - 2.16 2.16 - 2.17
Low: 1.87 - 1.89 1.89 - 1.9
Close: 2.06 - 2.08 2.08 - 2.1

Company Description

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Headline News

Thu, 23 Mar 2023
North American Morning Briefing : Traders Reassess -2- - Marketscreener.com

Mon, 27 Feb 2023
Healthcare Stocks on the Move Monday: CFRX, MLEC, SERA, UPH, RETA, APGN, GNPX, COSM - InvestorsObserver

Mon, 27 Feb 2023
ContraFect Corp (CFRX) Up 41.29% in Premarket Trading - InvestorsObserver

Mon, 27 Feb 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... - Investing.com

Mon, 27 Feb 2023
3 Short Squeeze Penny Stocks To Watch After CFRX Stock Explodes - Penny Stocks

Mon, 27 Feb 2023
Pre-market Movers: MLEC, CFRX, AWIN, TGNA, BRMKā€¦ - Nasdaq

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 1 (M)
Shares Float 0 (M)
% Held by Insiders 2 (%)
% Held by Institutions 12.1 (%)
Shares Short 38 (K)
Shares Short P.Month 52 (K)

Stock Financials

EPS -102.06
EPS Est Next Qtl -0.11
EPS Est This Year -0.44
EPS Est Next Year -0.42
Book Value (p.s.) -6.31
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -79.7
Return on Equity (ttm) -239.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -49.32
Qtrly Earnings Growth 0
Operating Cash Flow -45 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -0.03
PEG Ratio 0
Price to Book value -0.33
Price to Sales 0
Price to Cash Flow -0.07

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-02-03
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.